The study of XPro™ for Alzheimer's disease
Inmune Bio, Inc is starting a new clinical trial of Study to Assess the Efficacy of XPro™ in Patients With Mild Alzheimer's Disease With Biomarkers of Inflammation.
This study is designed as a double-blind randomized, placebo-controlled, study investigating the safety, tolerability, and efficacy of XPro™ in patients with mild AD with inflammation (ADi). The planned dose is 1.0 mg/kg of XPro™ and matching placebo.
The clinical trial started in February 28, 2022 and will continue throughout June 19, 2023.
Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) will be primary outcome measure. Change in the Early and Mild Alzheimer's cognitive composite (EMACC) from Baseline to Week 24 in the following assessments: International Shopping List Test-Immediate recall (Word List learning Test) Digit Span Forward and Backward Category Fluency Test (DKEFS) Letter Fluency Test (DKEFS) Trail Making Test Parts A and B Digit Symbol Coding Test To assess the efficacy of XPro™ compared with placebo on cognitive performance in patients with mild AD.
The contacts and locations are the INmune Bio Investigational Site, Macquarie Park, New South Wales, Australia. For more details: https://ichgcp.net/clinical-trials-registry/NCT05318976.
